PTEN's Role in Predicting Colorectal Cancer Response to Cetuximab
Author Information
Author(s): Razis Evangelia, Briasoulis Evangelos, Vrettou Eleni, Skarlos Dimosthenis V, Papamichael Dimitrios, Kostopoulos Ioannis, Samantas Epaminontas, Xanthakis Ioannis, Bobos Mattheos, Galanidi Eleni, Bai Maria, Gikonti Ioanna, Koukouma Alona, Kafiri Georgia, Papakostas Pavlos, Kalogeras Konstantine T, Kosmidis Paris, Fountzilas George
Primary Institution: Hellenic Cooperative Oncology Group
Hypothesis
Can PTEN and EGFR predict the response to cetuximab in colorectal cancer patients?
Conclusion
PTEN may be a key factor in determining the effectiveness of cetuximab treatment in colorectal cancer.
Supporting Evidence
- PTEN loss was associated with a higher response rate to cetuximab.
- The study included 72 patients with colorectal cancer.
- Median follow-up was 53 months from diagnosis.
- 53% of patients had died at the time of analysis.
Takeaway
This study looked at how a protein called PTEN might help doctors know if a cancer treatment will work for patients with colorectal cancer.
Methodology
Patients with colorectal cancer treated with cetuximab were analyzed for PTEN and EGFR expression using IHC and FISH.
Potential Biases
Potential biases due to the retrospective nature and varied treatment regimens.
Limitations
The study is retrospective and the patient population is heterogeneous.
Participant Demographics
{"median_age":60,"sex_distribution":{"male":40,"female":32},"tumor_location":{"left_sided":52,"right_sided":20}}
Statistical Information
P-Value
0.042
Statistical Significance
p = 0.042
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website